Post-Induction Treatment of Childhood Acute Lymphocytic Leukemia

Publisher Website
Google Scholar
Abstract
To the Editor: The report by the members of the Cancer and Leukemia Group B (March 3 issue) comparing intermediate-dose methotrexate with cranial irradiation provides important information about the treatment of childhood acute lymphocytic leukemia.1 However, the authors inaccurately cited a Children's Cancer Study Group publication that addressed the effect of an isolated Central-nervous-system relapse on subsequent bone-marrow remission and survival.2 We reported data on the effect of Central-nervous-system relapse after inadequate Central-nervous-system prophylaxis. Also contained in our report was the outcome in a smaller group of patients who had received adequate Central-nervous-system prophylaxis and in whom meningeal leukemia subsequently . . .